Pros and cons of transcatheter aortic valve implantation (TAVI)

Juan A. Terre, Isaac George, Craig R. Smith

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Transcatheter aortic valve implantation (TAVI) or replacement (TAVR) was recently approved by the FDA for intermediate risk patients with severe aortic stenosis (AS). This technique was already worldwide adopted for inoperable and high-risk patients. Improved device technology, imaging analysis and operator expertise has reduced the initial worrisome higher complications rate associated with TAVR, making it comparable to surgical aortic valve replacement (SAVR). However, many answers need to be addressed before adoption in lower risk patients. This paper highlights the pros and cons of TAVI based mostly on randomized clinical trials involving the two device platforms approved in the United States. We focused our analysis on metrics that will play a key role in expanding TAVR indication in healthier individuals. We review the significance and gave a perspective on paravalvular leak (PVL), valve performance, valve durability, leaflet thrombosis, stroke and pacemaker requirement.

Original languageEnglish (US)
Pages (from-to)444-452
Number of pages9
JournalAnnals of Cardiothoracic Surgery
Volume6
Issue number5
DOIs
StatePublished - Sep 1 2017
Externally publishedYes

Fingerprint

Equipment and Supplies
Aortic Valve Stenosis
Aortic Valve
Surgical Instruments
Thrombosis
Randomized Controlled Trials
Stroke
Technology
Transcatheter Aortic Valve Replacement

Keywords

  • Leaflet thrombosis
  • Pacemaker
  • Paravalvular leak (PVL)
  • Paravalvular regurgitation
  • Review
  • Stroke
  • Surgical aortic valve replacement (SAVR)
  • Transcatheter aortic valve implantation (TAVI)
  • Transcatheter aortic valve replacement (TAVR)

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Pros and cons of transcatheter aortic valve implantation (TAVI). / Terre, Juan A.; George, Isaac; Smith, Craig R.

In: Annals of Cardiothoracic Surgery, Vol. 6, No. 5, 01.09.2017, p. 444-452.

Research output: Contribution to journalArticle

Terre, Juan A. ; George, Isaac ; Smith, Craig R. / Pros and cons of transcatheter aortic valve implantation (TAVI). In: Annals of Cardiothoracic Surgery. 2017 ; Vol. 6, No. 5. pp. 444-452.
@article{7c73a66970de4ccaaaee67804d11c287,
title = "Pros and cons of transcatheter aortic valve implantation (TAVI)",
abstract = "Transcatheter aortic valve implantation (TAVI) or replacement (TAVR) was recently approved by the FDA for intermediate risk patients with severe aortic stenosis (AS). This technique was already worldwide adopted for inoperable and high-risk patients. Improved device technology, imaging analysis and operator expertise has reduced the initial worrisome higher complications rate associated with TAVR, making it comparable to surgical aortic valve replacement (SAVR). However, many answers need to be addressed before adoption in lower risk patients. This paper highlights the pros and cons of TAVI based mostly on randomized clinical trials involving the two device platforms approved in the United States. We focused our analysis on metrics that will play a key role in expanding TAVR indication in healthier individuals. We review the significance and gave a perspective on paravalvular leak (PVL), valve performance, valve durability, leaflet thrombosis, stroke and pacemaker requirement.",
keywords = "Leaflet thrombosis, Pacemaker, Paravalvular leak (PVL), Paravalvular regurgitation, Review, Stroke, Surgical aortic valve replacement (SAVR), Transcatheter aortic valve implantation (TAVI), Transcatheter aortic valve replacement (TAVR)",
author = "Terre, {Juan A.} and Isaac George and Smith, {Craig R.}",
year = "2017",
month = "9",
day = "1",
doi = "10.21037/acs.2017.09.15",
language = "English (US)",
volume = "6",
pages = "444--452",
journal = "Annals of Cardiothoracic Surgery",
issn = "2225-319X",
publisher = "AME Publishing Company",
number = "5",

}

TY - JOUR

T1 - Pros and cons of transcatheter aortic valve implantation (TAVI)

AU - Terre, Juan A.

AU - George, Isaac

AU - Smith, Craig R.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Transcatheter aortic valve implantation (TAVI) or replacement (TAVR) was recently approved by the FDA for intermediate risk patients with severe aortic stenosis (AS). This technique was already worldwide adopted for inoperable and high-risk patients. Improved device technology, imaging analysis and operator expertise has reduced the initial worrisome higher complications rate associated with TAVR, making it comparable to surgical aortic valve replacement (SAVR). However, many answers need to be addressed before adoption in lower risk patients. This paper highlights the pros and cons of TAVI based mostly on randomized clinical trials involving the two device platforms approved in the United States. We focused our analysis on metrics that will play a key role in expanding TAVR indication in healthier individuals. We review the significance and gave a perspective on paravalvular leak (PVL), valve performance, valve durability, leaflet thrombosis, stroke and pacemaker requirement.

AB - Transcatheter aortic valve implantation (TAVI) or replacement (TAVR) was recently approved by the FDA for intermediate risk patients with severe aortic stenosis (AS). This technique was already worldwide adopted for inoperable and high-risk patients. Improved device technology, imaging analysis and operator expertise has reduced the initial worrisome higher complications rate associated with TAVR, making it comparable to surgical aortic valve replacement (SAVR). However, many answers need to be addressed before adoption in lower risk patients. This paper highlights the pros and cons of TAVI based mostly on randomized clinical trials involving the two device platforms approved in the United States. We focused our analysis on metrics that will play a key role in expanding TAVR indication in healthier individuals. We review the significance and gave a perspective on paravalvular leak (PVL), valve performance, valve durability, leaflet thrombosis, stroke and pacemaker requirement.

KW - Leaflet thrombosis

KW - Pacemaker

KW - Paravalvular leak (PVL)

KW - Paravalvular regurgitation

KW - Review

KW - Stroke

KW - Surgical aortic valve replacement (SAVR)

KW - Transcatheter aortic valve implantation (TAVI)

KW - Transcatheter aortic valve replacement (TAVR)

UR - http://www.scopus.com/inward/record.url?scp=85030255425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030255425&partnerID=8YFLogxK

U2 - 10.21037/acs.2017.09.15

DO - 10.21037/acs.2017.09.15

M3 - Article

AN - SCOPUS:85030255425

VL - 6

SP - 444

EP - 452

JO - Annals of Cardiothoracic Surgery

JF - Annals of Cardiothoracic Surgery

SN - 2225-319X

IS - 5

ER -